Hepatitis C Virus Infection and Rheumatic Diseases: The Impact of Direct-Acting Antiviral Agents

Rheumatic Disease Clinics of North America

Volumn 43, Issue 1, 2017, Pages 123-132

  Cacoub, Patrice ^a,b,c   Commarmond, Cloé ^a,b,c   Sadoun, David ^a,b,c   Desbois, Anne Claire ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b Sorbonne Université   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Arthralgia; Arthritis; Direct acting antiviral agents (DAA); Hepatitis C (HCV); Rheumatic disorders; Sicca syndrome; Treatment; Vasculitis

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; AUTOANTIBODY; AZATHIOPRINE; BOCEPREVIR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLATASVIR; GLUCOCORTICOID; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; METHOTREXATE; PEGINTERFERON; PLACEBO; PREDNISONE; RIBAVIRIN; RITUXIMAB; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ANTIBODY PRODUCTION; ARTHRALGIA; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CARDIOVASCULAR DISEASE; CHRONIC HEPATITIS C; CRYOGLOBULINEMIA; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG CONTRAINDICATION; DRUG EFFICACY; HEPATITIS C; HUMAN; INFLAMMATORY DISEASE; KIDNEY DISEASE; LIVER DISEASE; MYALGIA; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SJOEGREN SYNDROME; TREATMENT DURATION; VASCULITIS; COMPLICATION; CONTRAINDICATIONS; HEPATITIS C, CHRONIC; IMMUNOLOGY; SJOGREN'S SYNDROME;

ANTIVIRAL AGENTS; ARTHRALGIA; AUTOANTIBODIES; CRYOGLOBULINEMIA; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MYALGIA; RHEUMATIC DISEASES; SJOGREN'S SYNDROME; VASCULITIS;

EID: 85001819711     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2016.09.011     Document Type: Review

References (60)

1. 1 Cacoub, P., Gragnani, L., Comarmond, C., et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 46:Suppl 5 (2014), S165–S173.
2. 2 Ferri, C., Sebastiani, M., Giuggioli, D., et al. Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. World J Hepatol 7 (2015), 327–343.
3. 3 Cacoub, P., Poynard, T., Ghillani, P., et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 42 (1999), 2204–2212.
4. 4 Cheng, Z., Zhou, B., Shi, X., et al. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chin Med J (Engl) 127 (2014), 1206–1210.
5. 5 Mohammed, R.H.A., ElMakhzangy, H.I., Gamal, A., et al. Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians. Clin Rheumatol 29 (2010), 1373–1380.
6. 6 Ogdie, A., Pang, W.G., Forde, K.A., et al. Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection. BMC Musculoskelet Disord, 16, 2015, 93.
7. 7 Landau, D.-A., Scerra, S., Sene, D., et al. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. J Rheumatol 37 (2010), 615–621.
8. 8 Ferri, C., Sebastiani, M., Giuggioli, D., et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 33 (2004), 355–374.
9. 9 Terrier, B., Semoun, O., Saadoun, D., et al. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum 63 (2011), 1748–1757.
10. 10 Cacoub, P., Renou, C., Rosenthal, E., et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 79 (2000), 47–56.
11. 11 Lee, Y.H., Ji, J.D., Yeon, J.E., et al. Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection. Ann Rheum Dis 57 (1998), 728–731.
12. 12 Saadoun, D., Thibault, V., Si Ahmed, S.N., et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 75:10 (2016), 1777–1782.
13. 13 Younossi, Z., Park, H., Henry, L., et al. Extra-hepatic manifestations of hepatitis C—a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 150:7 (2016), 1599–1608.
14. 14 Brito-Zerón, P., Gheitasi, H., Retamozo, S., et al. How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients. Arthritis Res Ther, 17, 2015, 250.
15. 15 Ramos-Casals, M., Loustaud-Ratti, V., De Vita, S., et al. Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore) 84 (2005), 81–89.
16. 16 Arrieta, J.J., Rodríguez-Iñigo, E., Ortiz-Movilla, N., et al. In situ detection of hepatitis C virus RNA in salivary glands. Am J Pathol 158 (2001), 259–264.
17. 17 Koike, K., Moriya, K., Ishibashi, K., et al. Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci U S A 94 (1997), 233–236.
18. 18 Khairy, M., El-Raziky, M., El-Akel, W., et al. Serum autoantibodies positivity prevalence in patients with chronic HCV and impact on pegylated interferon and ribavirin treatment response. Liver Int 33 (2013), 1504–1509.
19. 19 Hsieh, M.-Y., Dai, C.-Y., Lee, L.-P., et al. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. J Clin Pathol 61 (2008), 333–337.
20. 20 Himoto, T., Masaki, T., Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol, 2012, 2012, 871401.
21. 21 Terrier, B., Joly, F., Vazquez, T., et al. Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J Immunol 187 (2011), 6550–6563.
22. 22 Saadoun, D., Rosenzwajg, M., Joly, F., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365 (2011), 2067–2077.
23. 23 Zignego, A.L., Wojcik, G.L., Cacoub, P., et al. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Genes Immun 15 (2014), 500–505.
24. 24 Gragnani, L., Piluso, A., Giannini, C., et al. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors. Arthritis Rheum 63 (2011), 1446–1451.
25. 25 Caussin-Schwemling, C., Schmitt, C., Stoll-Keller, F., Study of the infection of human blood derived monocyte/macrophages with hepatitis C virus in vitro. J Med Virol 65 (2001), 14–22.
26. 26 Muramatsu, M., Kinoshita, K., Fagarasan, S., et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102 (2000), 553–563.
27. 27 Domont, F., Cacoub, P., Chronic hepatitis C virus infection, a new cardiovascular risk factor?. Liver Int 36 (2016), 621–627.
28. 28 Maruyama, S., Koda, M., Oyake, N., et al. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol 58 (2013), 11–15.
29. 29 Hsu, Y.-H., Hung, P.-H., Muo, C.-H., et al. Interferon-based treatment of hepatitis C virus infection reduces all-cause mortality in patients with end-stage renal disease: an 8-year nationwide cohort study in Taiwan. Medicine (Baltimore), 94, 2015, e2113.
30. 30 Hsu, Y.-C., Lin, J.-T., Ho, H.J., et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59 (2014), 1293–1302.
31. 31 Hsu, C.-S., Kao, J.-H., Chao, Y.-C., et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther 38 (2013), 415–423.
32. 32 Elkrief, L., Chouinard, P., Bendersky, N., et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology 60 (2014), 823–831.
33. 33 Huang, Y.-W., Yang, S.-S., Fu, S.-C., et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study. Hepatology 60 (2014), 807–814.
34. 34 Hung, C.-H., Lee, C.-M., Wang, J.-H., et al. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer 128 (2011), 2344–2352.
35. 35 Eslam, M., Aparcero, R., Kawaguchi, T., et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 34 (2011), 297–305.
36. 36 Patel, R., Mikuls, T.R., Richards, J.S., et al. Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection. Arthritis Care Res 67 (2015), 467–474.
37. 37 Mazzaro, C., Zorat, F., Caizzi, M., et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 42 (2005), 632–638.
38. 38 Saadoun, D., Resche-Rigon, M., Thibault, V., et al. Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 54 (2006), 3696–3706.
39. 39 Cacoub, P., Comarmond, C., Domont, F., et al. Cryoglobulinemia vasculitis. Am J Med 128 (2015), 950–955.
40. 40 Yang, D., Arkfeld, D., Fong, T.-L., Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon-α2a treatment for chronic hepatitis C infection. J Rheumatol, 37, 2010, 1777.
41. 41 Cacopardo, B., Benanti, F., Pinzone, M.R., et al. Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature. BMC Res Notes, 6, 2013, 437.
42. 42 Onishi, S., Nagashima, T., Kimura, H., et al. Systemic lupus erythematosus and Sjögren's syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C. Lupus 19 (2010), 753–755.
43. 43 Stübgen, J.-P., Interferon alpha and neuromuscular disorders. J Neuroimmunol 207 (2009), 3–17.
44. 44 Gragnani, L., Fabbrizzi, A., Triboli, E., et al. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. Dig Liver Dis 46 (2014), 833–837.
45. 45 Saadoun, D., Resche Rigon, M., Pol, S., et al. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 62 (2015), 24–30.
46. 46 Afdhal, N., Zeuzem, S., Kwo, P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
47. 47 Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370 (2014), 211–221.
48. 48 Sulkowski, M.S., Vargas, H.E., Di Bisceglie, A.M., et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 150 (2016), 419–429.
49. 49 Pol, S., Corouge, M., Vallet-Pichard, A., Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepat Med 8 (2016), 21–26.
50. 50 Sise, M.E., Bloom, A.K., Wisocky, J., et al. Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 63 (2016), 408–417.
51. 51 Kondili, L.A., Weimer, L.E., Mallano, A., et al. HCV-related mixed cryoglobulinemia: data from PITER, a nationwide Italian HCV cohort study. J Hepatol, 64, 2016, S618.
52. 52 De Vita, S., Quartuccio, L., Isola, M., et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 64 (2012), 843–853.
53. 53 Sneller, M.C., Hu, Z., Langford, C.A., A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 64 (2012), 835–842.
54. 54 Saadoun, D., Resche Rigon, M., Sene, D., et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 116 (2010), 326–334 [quiz: 504–5].
55. 55 Dammacco, F., Tucci, F.A., Lauletta, G., et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 116 (2010), 343–353.
56. 56 Sène, D., Ghillani-Dalbin, P., Amoura, Z., et al. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 60 (2009), 3848–3855.
57. 57 Dammacco, F., Sansonno, D., Han, J.H., et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 84 (1994), 3336–3343.
58. 58 Hausfater, P., Cacoub, P., Assogba, U., et al. Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis. Nephron 91 (2002), 627–630.
59. 59 Younossi, Z.M., Stepanova, M., Marcellin, P., et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 61 (2015), 1798–1808.
60. 60 Byrnes, V., Miller, A., Lowry, D., et al. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol 56 (2012), 549–556.